Sign Out
Tab: Concomitant therapy with HMG-CoA reductase inhibitors (e.g. lovostatin, pravastatin, simvastatin), or fenofibric acid derivatives (e.g. gemfibrozil) should be avoided, if use is warranted administer cautiously.
Concomitant therapy with anticoagulants: exercise caution.
Cholelithiasis.
Diabetic patients; Increased risk of myopathies including rhabdomyolysis.
Elderly patients; Increased risk of myopathies including rhabdomyolysis.
Hypothyroidism; Increased risk of myopathies including rhabdomyolysis.
Hypersensitivity reactions have occurred, including skin rashes requiring hospitalization and Stevens-Johnson syndrome.
Myopathies may occur; Discontinuation of therapy may be warranted.
Pancreatitis.
Renal dysfunction; Increased risk of myopathies including rhabdomyolysis.
Serum transaminases (AST and ALT) increases of more than 3 times the upper limit of normal have been reported; monitoring is recommended, discontinuation of therapy may be warranted.
